Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2012. The document is a statement regarding GSK's tender offer to acquire Human Genome Sciences (HGS) for US$13.00 per share in cash, following the HGS Board of Directors' decision to recommend against the offer.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, or debt metrics for GSK. Specific financial data points related to the target company and the transaction include:
- Tender Offer Price: US$13.00 per share in cash.
- Offer Premium: 81 percent over HGS's closing share price of US$7.17 on April 18, 2012.
- Expected Cost Synergies: At least $200 million.
- Benlysta Sales: $25.7 million in Q4 2011 and $31.2 million in Q1 2012 (US sales).
Material Changes and Transaction Details
The primary material event is the HGS Board's recommendation against GSK's unsolicited tender offer. GSK maintains that the offer represents full and fair value, incorporating the value of Benlysta, darapladib, albiglutide, and HGS's pipeline. The offer is not conditioned on due diligence or financing. GSK owns the vast majority of the economics for albiglutide and darapladib, with HGS entitled to conditional milestones and royalties (mid-single digit for albiglutide; 10 percent royalty plus potential profit share for darapladib).
Guidance, Outlook, and Risks
Outlook and Strategy: GSK believes the combination aligns with its long-term strategy of sustainable growth, simplifying its business model, and enhancing R&D returns. The company intends to proceed with the tender offer, which is scheduled to close on June 7, 2012, while expressing a preference for a friendly transaction.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements, noting risks that actual results may differ materially. Specific risks include the execution risk inherent in HGS achieving future growth objectives and the timeline for clinical trials (darapladib Phase III trials expected to finish no earlier than 2013 and 2014).
Investor Verification Checklist
- Verify the final status of the tender offer and whether it closes on June 7, 2012, given the HGS Board's opposition.
- Review the "Offer to Purchase" and related materials filed with the SEC for detailed terms and conditions.
- Confirm the current progress of darapladib and albiglutide clinical trials against the stated timelines (2013/2014).
- Assess the impact of the potential acquisition on GSK's capital deployment and R&D pipeline.